Suppr超能文献

多囊卵巢综合征患者未使用促性腺激素的体外成熟与超排卵体外受精的比较:一项非劣效性随机对照试验。

In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial.

机构信息

Department of Obstetrics and Gynecology, Centre for Reproductive Medicine, Peking University Third Hospital, Beijing, China.

National Clinical Research Centre for Obstetrics and Gynecology, Beijing, China.

出版信息

Hum Reprod. 2022 Jan 28;37(2):242-253. doi: 10.1093/humrep/deab243.

Abstract

STUDY QUESTION

Does in vitro maturation (IVM) result in non-inferior cumulative live birth rates compared to those after standard in vitro fertilization (IVF) in infertile women with polycystic ovary syndrome (PCOS)?

SUMMARY ANSWER

One cycle of IVM, without any stimulation, was inferior to one cycle of standard IVF in women with PCOS in terms of 6-month cumulative live birth rates, when choosing single vitrified-warmed blastocyst transfer.

WHAT IS KNOWN ALREADY

IVM is an emerging alternative treatment for women with PCOS who need assisted reproductive technology. Since a minimal or even zero dose of gonadotropins are required in the IVM procedure, the occurrence of ovarian hyperstimulation syndrome (OHSS) is eliminated. Only one clinical trial comparing the pregnancy outcome between IVM with FSH priming and IVF has been reported. However, it is still unknown whether IVM treatment without any stimulation can offer a similar live birth outcome in women with PCOS as compared to that in women receiving the standard IVF procedure with ovarian stimulation.

STUDY DESIGN, SIZE, DURATION: This single-centre, open-label randomized controlled non-inferiority trial in an academic infertility centre in China was performed between March 2018 and July 2019.

PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged 20-38 years with PCOS and infertility scheduled for their first IVF attempt were eligible. In total, 351 women were randomly allocated to receive one cycle of unstimulated IVM (n = 175) or one cycle of standard IVF with a flexible GnRH antagonist protocol and hCG as ovulatory trigger (n = 176). A freeze-all and single blastocyst transfer strategy was used in both groups. The primary outcome was ongoing pregnancy (leading to live birth) within 6 months after randomization. A non-inferiority margin of 15% was considered.

MAIN RESULTS AND THE ROLE OF CHANCE

The IVM procedure without additional gonadotropin resulted in a lower ongoing pregnancy (leading to live birth) within 6 months after randomization compared to standard IVF treatment (22.3% vs. 50.6%; rate difference -28.3%; 95% confidence interval [CI]: -37.9% to -18.7%). Moderate-severe OHSS did not occur in the IVM group, while in the IVF group, ten women (5.7%) had moderate OHSS and one woman (0.6%) had severe OHSS. There was no statistically significant difference in the occurrence of obstetric and perinatal complications.

LIMITATIONS, REASONS FOR CAUTION: The trial was conducted using an IVM protocol without additional stimulation in a single centre, which may limit its generalizability. In addition, a GnRH agonist trigger rather than hCG for IVF stimulation in women with PCOS would be more consistent with current clinical practice.

WIDER IMPLICATIONS OF THE FINDINGS

Although IVM is considered to be a convenient, inexpensive and safe alternative to IVF for women with PCOS, our results indicated that one cycle of IVM without any stimulation was inferior to one cycle of standard IVF in terms of the cumulative live birth rate. The inferiority of IVM without ovarian stimulation could be mainly due to the limitations in the developmental potential of embryos. Further IVM development should be tested and validated in a freeze-only and blastocyst transfer setting. Further RCTs are needed to evaluate the effectiveness and safety of other IVM protocols or multiple cycles of IVM compared to IVF.

STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Key Research and Development Program of China (2016YFC1000201 and 2018YFC1002104) and the National Science Foundation of China (81730038). B.W.M. is supported by a NHMRC Investigator grant (GNT1176437). All other authors declare no competing interests.

TRIAL REGISTRATION NUMBER

Clinicaltrials.gov NCT03463772.

TRIAL REGISTRATION DATE

29 January 2018.

DATE OF FIRST PATIENT’S ENROLMENT: 16 March 2018.

摘要

研究问题

在多囊卵巢综合征(PCOS)不孕妇女中,与标准体外受精(IVF)相比,体外成熟(IVM)是否会导致累积活产率无差异?

总结答案

在选择单个玻璃化冷冻-解冻囊胚移植的情况下,与 PCOS 妇女的标准 IVF 相比,没有任何刺激的一个周期的 IVM 周期在 6 个月累积活产率方面较差。

已知情况

IVM 是一种新兴的治疗多囊卵巢综合征妇女的辅助生殖技术替代方法。由于在 IVM 过程中仅需要最低或甚至零剂量的促性腺激素,因此消除了卵巢过度刺激综合征(OHSS)的发生。仅有一项比较 IVM 与 FSH 启动和 IVF 之间妊娠结局的临床试验报告。然而,目前尚不清楚与接受卵巢刺激的标准 IVF 程序的妇女相比,未经任何刺激的 IVM 治疗是否可以为 PCOS 妇女提供相似的活产结局。

研究设计、大小和持续时间:这项单中心、开放标签、随机对照非劣效性临床试验在中国的一家学术不孕中心进行,时间为 2018 年 3 月至 2019 年 7 月。

参与者/材料、设置、方法:年龄在 20-38 岁、患有 PCOS 和不孕症并计划进行首次 IVF 尝试的女性有资格参加。共有 351 名女性被随机分配接受一个周期的未刺激 IVM(n = 175)或一个周期的标准 IVF,采用灵活的 GnRH 拮抗剂方案和 hCG 作为排卵触发(n = 176)。两组均采用全冷冻和单个囊胚移植策略。主要结局是随机分组后 6 个月内的持续妊娠(导致活产)。考虑了 15%的非劣效性边缘。

主要结果和机会的作用

与标准 IVF 治疗相比,没有额外促性腺激素的 IVM 程序导致随机分组后 6 个月内的持续妊娠(导致活产)较低(22.3%对 50.6%;率差-28.3%;95%置信区间[CI]:-37.9%至-18.7%)。在 IVM 组中没有发生中重度 OHSS,而在 IVF 组中,有 10 名女性(5.7%)发生中度 OHSS,1 名女性(0.6%)发生重度 OHSS。两组的产科和围产期并发症发生率无统计学差异。

局限性、谨慎的原因:该试验是在单一中心使用没有额外刺激的 IVM 方案进行的,这可能限制了其普遍性。此外,对于 PCOS 妇女,用 GnRH 激动剂而不是 hCG 触发 IVF 刺激会更符合当前的临床实践。

研究结果的更广泛意义

尽管 IVM 被认为是多囊卵巢综合征妇女的一种方便、廉价和安全的 IVF 替代方法,但我们的结果表明,与标准 IVF 相比,未经任何刺激的一个周期的 IVM 在累积活产率方面较差。未经卵巢刺激的 IVM 劣势可能主要归因于胚胎发育潜力的限制。应该在仅冷冻和囊胚移植的设置中进一步测试和验证 IVM 的发展。需要进一步的 RCT 来评估与 IVF 相比,其他 IVM 方案或多个 IVM 周期的有效性和安全性。

研究资金/利益冲突:本研究得到了中国国家重点研发计划(2016YFC1000201 和 2018YFC1002104)和国家自然科学基金(81730038)的支持。B.W.M. 得到了 NHMRC 研究员资助(GNT1176437)。所有其他作者均声明不存在竞争利益。

临床试验注册号

Clinicaltrials.gov NCT03463772。

临床试验注册日期

2018 年 1 月 29 日。

第一例患者入组日期

2018 年 3 月 16 日。

相似文献

8
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Cochrane Database Syst Rev. 2020 Dec 21;12(12):CD006105. doi: 10.1002/14651858.CD006105.pub4.

引用本文的文献

1
Minimising OHSS in women with PCOS.
Front Endocrinol (Lausanne). 2025 Mar 13;16:1507857. doi: 10.3389/fendo.2025.1507857. eCollection 2025.
2
Insights gained from a cleavage-stage embryo freeze-all policy in in vitro maturation cycles.
J Assist Reprod Genet. 2025 Apr 2. doi: 10.1007/s10815-025-03469-7.
3
In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.
Cochrane Database Syst Rev. 2025 Feb 6;2(2):CD006606. doi: 10.1002/14651858.CD006606.pub5.
5
Current status and hotspots of in vitro oocyte maturation: a bibliometric study of the past two decades.
J Assist Reprod Genet. 2025 Feb;42(2):459-472. doi: 10.1007/s10815-024-03272-w. Epub 2024 Sep 25.
7
EPAS1 expression contributes to maintenance of the primordial follicle pool in the mouse ovary.
Sci Rep. 2024 Apr 16;14(1):8770. doi: 10.1038/s41598-024-59382-z.
8
In vitro maturation (IVM) of human immature oocytes: is it still relevant?
Reprod Biol Endocrinol. 2023 Nov 22;21(1):110. doi: 10.1186/s12958-023-01162-x.
10
IVM of human immature oocytes for infertility treatment and fertility preservation.
Reprod Med Biol. 2023 Jul 11;22(1):e12524. doi: 10.1002/rmb2.12524. eCollection 2023 Jan-Dec.

本文引用的文献

1
In vitro maturation: a committee opinion.
Fertil Steril. 2021 Feb;115(2):298-304. doi: 10.1016/j.fertnstert.2020.11.018. Epub 2020 Dec 24.
3
Human Chorionic Gonadotropin Priming Does Not Improve Pregnancy Outcomes of PCOS-IVM Cycles.
Front Endocrinol (Lausanne). 2020 Apr 30;11:279. doi: 10.3389/fendo.2020.00279. eCollection 2020.
4
A variant of human growth differentiation factor-9 that improves oocyte developmental competence.
J Biol Chem. 2020 Jun 5;295(23):7981-7991. doi: 10.1074/jbc.RA120.013050. Epub 2020 Apr 29.
7
Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles.
J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9.
8
In Vitro Maturation of Oocytes in Women at Risk of Ovarian Hyperstimulation Syndrome-A Prospective Multicenter Cohort Study.
Int J Fertil Steril. 2019 Apr;13(1):38-44. doi: 10.22074/ijfs.2019.5452. Epub 2019 Jan 6.
9
In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.
Cochrane Database Syst Rev. 2018 Nov 15;11(11):CD006606. doi: 10.1002/14651858.CD006606.pub4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验